|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/30 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 3254695 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17171169.0 |
| Date of filing the European patent application | 2013-05-21 | |
| (97) | Date of publication of the European application | 2017-12-13 |
| (45) | Date of publication and mention of the grant of the patent | 2020-09-09 |
| (46) | Date of publication of the claims translation | 2020-12-28 |
| (30) | Number | Date | Country code |
| PCT/EP2012/0022 | 2012-05-23 | WO |
| (72) |
SAHIN, Ugur, DE
TÜRECI, Özlem, DE
MITNACHT-KRAUS, Rita, DE
JACOBS, Stefan, Denis, DE
UTSCH, Magdalena, Jadwiga, DE
HEINZ, Cornelia, Adriana, Maria, DE
STADLER, Christiane, Regina, DE
|
| (73) |
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige Gmb,
Freiligrathstrasse 12, 55131 Mainz,
DE
Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-Chome, Chuo-ku Tokyo 103-8411, JP |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kombinuota terapija, apimanti antikūnus prieš klaudiną 18.2, skirta vėžio gydymui |
| COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER |
| Payment date | Validity (years) | Amount | |
| 2024-05-02 | 12 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-02-14 |